Volume : 09, Issue : 04, April – 2022

Title:

40.FORMULATION, DEVELOPMENT AND EVALUATION OF TRANSFERSOMAL GEL OF MICONAZOLE NITRATE
‏‬

Authors :

Sanjeev Kurmi, Mr. Pushpendra Kumar Khangar*, Dr. Vivek Jain, Dr. Sunil Kumar Jain

Abstract :

Miconazole nitrate (MCN) is an antifungal drug used for treatment of superficial fungal infections. However, it has low skin permeability. Hence, the objective of this study was to prepare miconazole nitrate using transfersomes to overcome the barrier function of the skin. MCN transfersomes were prepared using a thin lipid film hydration technique. The prepared transfersomes were evaluated with respect to morphological study, particle size analysis, zeta potential, % entrapment efficiency and quantity of in vitro drug released to obtain an optimized formulation. The optimized formulation of MCN transfersomes was incorporated into a Poloxamer 407, HPMC K15, propylene glycol gel base which was evaluated for pH, rheological study, content uniformity, in vitro drug release study and stability studies. The average vesicle size of optimized formulation (F-4) observed as 187.38±2.61µm, zeta potential observed as -44.68±1.45mV and %EE was found as 82.86±5.27%. The in vitro release study suggested that there was an inverse relationship between EE% and in vitro release. The kinetic analysis of all release profiles was found to follow Korsemeyer-peppas model. Stability studies for prepared formulations were also performed. Transferosomal vesicles stored at refrigeration condition were physically stable. Therefore, miconazole nitrate in the form of transfersomes has the ability to penetrate the skin, overcoming the stratum corneum barrier.
Keywords: Transfersomes; Miconazole nitrate; Entrapment efficiency; Poloxamer 407.

Cite This Article:

Please cite this article in press Pushpendra Kumar Khangar et al, Formulation, Development And Evaluation Of Transfersomal Gel Of Miconazole Nitrate., Indo Am. J. P. Sci, 2022; 09(04).,

Number of Downloads : 10

References:

1. Kim JY. Human fungal pathogens: why should we learn? J Microbiol 2016; 54(3):145-8.
2. Hainer BL. Dermatophyte infections. Am Fam Phys 2003; 67(1):101-8.
3. Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed 2005; 4(5):305-10.
4. Gretzula J, Penneys NS. Complex viral and fungal skin lesions of patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1987; 16(6):1151-4.
5. Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol 2015; 81(5):457-63.
6. Hawkins DM, Smidt AC. Superficial fungal infections in children. Pediatr Clin North Am 2014; 61(2):443-55.
7. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North Am Perspect Drugs 1998; 55(5):645-74.
8. Watanabe S. Dermatomycosis–classification, etiology, pathogenesis, and treatment. Nihon Rinsho 2008; 66(12):2285-9.
9. Pandit, J.; Garg, M.; Jain, N. Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection. J. Liposome Res. 2014, 24, 163–3169.
10. El Zaafarany, G.; Awad, G.; Holayel, S.; Mortada, N. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int. J. Pharm. 2010, 397, 164–172.
11. Sanap GS, dan Mohanta P. Development of miconazole nitrate controlled release formulations based on SLN and NLC for topical delivery. Int J Pharm Pharm Sci 2014; 6:393-9.
12. Samira S, Ali MT, Fakhr S, Saed D, dan Hamidrwza M. Pharmaceutical nanoemulsion and their potential topical and transdermal applications. Iran J Pharm Sci 2015; 7:139-50.
13. Gossel TA. Topical antifungal products. U.S Pharm J 1985;10:44-6.
14. Tenjarla S, Puranajoti P, Kasina R, Mandal T. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J Pharm Sci 1998;87:425-9.
15. Aljaeid, B.; Hosny, K. Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity. Int. J. Nanomed. 2016, 11, 441–447.
16. Mir-Palomo, S.; Nácher, A.; Díez-Sales, O.; Busó, M.; Caddeo, C.; Manca, M.; Manconi, M.; Fadda, A.; Saurí, A. Inhibition of skin inflammation by baicalin ultradeformable vesicles. Int. J. Pharm. 2016, 511, 23–29.
17. El Zaafarany G., Awad G., Holayel S., Mortada N. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int. J. Pharm. 2010;397:164–172.
18. Abdallah M. Transfersomes as a transdermal drug delivery system for enhancement the antifungal activity of nystatin. Int. J. Pharm. Pharm. Sci. 2013;5:560–567.
19. Mona Qushawy, Ali Nasr, Mohammed Abd-Alhaseeb and Shady Swidan. Design, Optimization and Characterization of a Transfersomal Gel Using Miconazole Nitrate for the Treatment of Candida Skin Infections. Pharmaceutics 2018, 10, 26.
20. Schmolka IR. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6(6): 571–582.
21. Mahmoud M Omar, Omiya Ali Hasan, Amani M El Sisi. Preparation and optimization of lidocaine transferosomal gel containing permeation enhancers: a promising approach for enhancement of skin permeation. International Journal of Nanomedicine 2019:14 1551–1562.
22. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: A controlled and novel drug delivery system. Biol Pharm Bull 2011; 34(7): 945- 953.